Bpc-157
Phase 1
Bpc-157 is one of 21 therapeutic programs targeting Rotator Cuff Tear. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
23 competitors in Rotator Cuff Tear
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Marcaine
IInnocoll
Approved
Ultram
WWim Janssens
Approved
Decadron
AAspen Global Incorporated
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Neurontin
VViatris Specialty LLC
Approved
Valium
Akero TherapeuticsApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Suboxone
IIndivior Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Bpc-157. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Arkansas